Mid to Long-Term Echocardiographic Follow-up of Patients Undergoing Transcatheter Tricuspid Valve-in-Valve Replacement for Degenerated Bioprosthetic Valves: First Single-Center Report from Iran

Mohammad Sahebjam, MD, Alimohammad Haji Zeinali, MD, Kyomars Abbasi, MD, Solmaz Borjian, MD

Abstract

Background: Transcatheter tricuspid valve-in-valve (TTViV) replacement has become an alternative treatment in high-risk patients with bioprosthetic valve degeneration. This is the first report on the mid to long-term echocardiographic findings of patients who underwent TTViV replacement in a cardiac referral center in Iran.

Methods: Data of 12 patients, consisting of 11 women and 1 man, who underwent TTViV replacement between 2015 and 2021 were reviewed retrospectively. The patients underwent echocardiography before the procedure and at a mean follow-up time of 3.17±1.75 years.

Results: All the patients had New York Heart Association (NYHA) function class III/IV before TTViV. Six patients had tricuspid regurgitation, 1 had tricuspid stenosis, and 5 had both. All the patients had successful TTViV. The mean time from the initial valve surgery to TTViV was 6.25±2.45 years. At follow-up, 2 patients had died: 1 due to COVID-19 pneumonia and 1 without a known cause. The remaining 10 patients experienced improvements in the NYHA functional class. Echocardiographic measures showed significant improvements. Transvalvular mean gradient pressure decreased from 7.08±1.98 mm Hg to 5.29±1.63 mm Hg (P=0.028), tricuspid valve pressure half time decreased from 245.00±49.46 ms to 158.64±57.41 ms (P=0.011), tricuspid regurgitation gradient decreased from 39.91±7.31 mm Hg to 26.72±8.99 mm Hg, and left ventricular ejection fraction increased from 47.71±4.70% to 49.79±4.58% (P=0.046). There was no significant paravalvular or transvalvular leakage at follow-up.

Conclusion: This is a single-center report on the mid and long-term echocardiographic follow-up of patients after TTViV replacement. Our study showed that TTViV was a safe and efficient method in treating high-risk patients with degenerated bioprosthetic tricuspid valves and had favorable echocardiographic and clinical results.

J Teh Univ Heart Ctr 2022;17(3):112-118

This paper should be cited as: Sahebjam M, Haji Zeinali A, Abbasi K, Borjian S. Mid to Long-Term Echocardiographic Follow-up of Patients Undergoing Transcatheter Tricuspid Valve-in-Valve Replacement for Degenerated Bioprosthetic Valves: First Single-Center Report from Iran. J Teh Univ Heart Ctr 2022;17(3):112-118.

Keywords: Tricuspid valve insufficiency; Echocardiography; Bioprosthesis; Tricuspid valve stenosis
**Introduction**

Bioprosthetic valves are mostly preferred to mechanical valves for right-side valve replacement, chiefly because there is no need for long-term anticoagulation therapy after bioprosthetic valve replacement in contrast to mechanical valve replacement.¹

On the other hand, bioprosthetic valves have undergone degenerative changes over time,² leading to valve regurgitation or stenosis, which causes symptoms and in the long-term, ventricular dysfunction. Patients who become symptomatic due to bioprosthetic valve degeneration and need reoperation are at high risk for redo surgery, primarily due to existing comorbidities such as diabetes and chronic kidney disease, as well as a history of prior cardiac surgery.³ According to the Society of Thoracic Surgeons registry, reoperation for tricuspid valve replacement is a high-risk surgical operation. Hence, transcatheter tricuspid valve-in-valve (TTViV) replacement has become an attractive alternative treatment method in patients with degenerated bioprosthetic tricuspid valves.⁴

In the current study, we present a brief single-center report on the mid to long-term follow-up echocardiographic findings of patients who underwent TTViV replacement in our institution. To our knowledge, the echocardiographic follow-up of patients following TTViV has not been reported in Iran previously.

**Methods**

Twelve patients underwent TTViV replacement in Tehran Heart Center, Tehran, Iran, between 2015 and 2021. The procedure was performed if patients had deteriorating clinical symptoms and were at high risk for cardiac reoperation. The 12 patients’ demographic and clinical data were reviewed retrospectively. Data regarding primary bioprosthetic valves, including the kind and size of the valve, were obtained from initial valve replacement surgery records. Transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) were performed using GE S60 and Phillips Affinity 70 ultrasound machines. The internal diameters of the bioprosthetic valves were measured using a dedicated application (Valve-in-Valve by Vinayak Bapat) and in some cases using multidetector computed tomography (CT) scan. The patients had been presented and discussed by the heart team and chosen for TTViV replacement after surgical reoperation risk assessments and the patients’ preferences.

Tricuspid bioprosthetic valve degeneration was defined as stenosis with the thickening and calcification of the leaflets and/or regurgitation. According to the current guidelines,⁵ normal functioning tricuspid prosthetic valves have a transvalvular mean pressure gradient (MPG) of less than 6 mmHg. Therefore, in our study, a transvalvular MPG of 6 mmHg or greater was defined as stenosis. In addition, a regurgitation severity degree of equal to or greater than moderate was considered significant regurgitation.

Right femoral vein catheterization was performed under general anesthesia or conscious sedation.⁶ After the insertion of the guidewire into the pulmonary wedge, an Edwards balloon was inserted. In 2 patients, predilation was performed using an Edwards balloon number 23. Ventricular pacing was performed in 1 patient. In 2 other patients, transient asystole was achieved using adenosine. In the rest of the patients, rapid pacing or transient arrest was not necessary. Then, under TEE or TTE and fluoroscopic guidance, one of bioprosthetic Edwards SAPIEN valves (SAPIEN XT or SAPIEN 3) was deployed. Postdilation with balloon expansion was not needed in our patients. After the procedure, paravalvular and transvalvular regurgitation and the gradient measures of the newly inserted valve were evaluated using TEE or TTE. Procedure complications were also evaluated.

To rule out subvalvular clots as the underlying cause of valve stenosis, we commenced anticoagulation treatment in patients with tricuspid stenosis not having received anticoagulants previously. These patients were re-evaluated after 2 to 3 weeks; subsequently, the patients became candidates for TTViV. In patients with tricuspid stenosis already under anticoagulation therapy, the anticoagulant dose was increased to the safest dosage.

The outcome of interest after the TTViV procedure was defined as an improvement in transvalvular or paravalvular regurgitation, valve gradient, size and function of the right ventricle, size of the right atrium, and pulmonary artery pressure (if it was technically feasible). All these parameters were measured before the procedure and at follow-up.

Continuous variables were expressed as the mean ± the standard deviation (SD). Echocardiographic measurements before and after the procedure were compared using the Wilcoxon Signed Rank test. A P value of 0.05 or less was used to identify significant changes. We used IBM SPSS Statistics, version 26, for the statistical analyses.

**Results**

The study population consisted of 12 patients: 1 man and 11 women. The mean age of the patients was 59.67±11.70 years (range=33–73). All 12 patients had degenerated biologic tricuspid valves prior to the procedure, including regurgitation and/or stenosis. Six patients presented with isolated tricuspid regurgitation, 1 had isolated tricuspid stenosis, and 5 had concomitant tricuspid stenosis and tricuspid regurgitation. One patient had a history of only tricuspid valve replacement surgery, and 11 patients had a history of other valve surgeries, coronary artery bypass graft,
or other cardiac procedures in addition to tricuspid valve replacement. All the patients underwent a successful TTViV procedure. The mean time from the initial valve surgery to TTViV was 6.25±2.45 years.

The baseline characteristics of the study subjects including age, sex, New York Heart Association (NYHA) functional class, years after the initial surgery, and numbers and types of heart surgeries before TTViV are summarized in Table 1. All the patients had NYHA functional class III/ IV before the procedure. The baseline echocardiographic parameters and data related to the primary bioprosthetic valve are summarized in Table 2 and Table 3.

The patients were followed up for a mean of 3.17±1.75 years. Seven out of the 12 patients had a follow-up time of 3 years or longer. Two patients passed away during the follow-up period: 1 patient due to COVID-19 pneumonia and 1 patient without a known cause. Therefore, their assessments were incomplete. Ten living patients reported improvements in clinical symptoms and functional class at follow-up. Follow-up echocardiography was scheduled as follows: in the same admission after the TTViV procedure, 3 to 6 months and 1 year after the procedure, and then annually, except for a few patients who were absent in some follow-up sessions. In the follow-up echocardiography, no-more-than trivial transvalvular or paravalvular regurgitation was detected in the studied patients.

Follow-up echocardiographic parameters are summarized in Table 4, Figure 1, and Figure 2. In 1 patient, whose systolic pulmonary artery pressure was high after TTViV (40 mmHg), no significant change was observed in the NYHA functional class at follow-up (patient number 2). In the other 11 patients, the NYHA functional class improved to less

### Table 1. Baseline demographic and historical data of patients with tricuspid bioprosthetic valve degeneration

| Case No. | Age (y) | Sex | NYHA Functional Class | Time from the Initial Surgery (y) | Other Valve or Cardiac Surgeries | Number of Prior Heart Surgeries |
|----------|---------|-----|-----------------------|----------------------------------|---------------------------------|-------------------------------|
| 1        | 61      | F   | III-IV                | 7                                | MVR, AVR, Redo TVR, PPM        | 2                             |
| 2        | 70      | F   | IV                    | 8                                | CABG, MVR, TVR, LAA and PDA closure | 1                             |
| 3        | 33      | M   | III-IV                | 4                                | Redo TVR                       | 2                             |
| 4        | 53      | F   | III-IV                | 9                                | CMVC, MVR, TVR                 | 2                             |
| 5        | 48      | F   | III                   | 7                                | MVR, TVR                       | 1                             |
| 6        | 70      | F   | III                   | 5                                | MVR, AVR, Redo TVR             | 2                             |
| 7        | 73      | F   | III-IV                | 2                                | MVR, AVR, Redo TVR             | 2                             |
| 8        | 69      | F   | III-IV                | 8                                | MVR, Redo AVR, Redo TVR        | 2                             |
| 9        | 63      | F   | III                   | 3                                | MVR, TVR                       | 1                             |
| 10       | 61      | F   | III-IV                | 4                                | MVR, AVR, TVR, Septal myectomy  | 1                             |
| 11       | 65      | F   | III-IV                | 10                               | MVR, TVR                       | 1                             |
| 12       | 50      | F   | III-IV                | 5                                | ASD closure, MVR, Redo TVR      | 2                             |

NYHA, New York Heart Association; F, Female; M, Male; TV, tricuspid valve; MVR, Mitral valve replacement; AVR, Aortic valve replacement; PPM, Permanent pacemaker; CMVC, Closed mitral valve commissurotomy; CABG, Coronary artery bypass graft; LAA, Left atrial auricle; PDA, Patent ductus arteriosus; PTMC, Percutaneous trans-mitral commissurotomy; ASD, Atrial septal defect

### Table 2. Echocardiographic characteristics at baseline before TTViV

| Case No. | RV diameter (mm) | RV s' (cm/s) | RA area (mm2) | TV MPG (mm Hg) | TV PHT (ms) | Transvalvular regurgitation | Paravalvular regurgitation | TR gradient (mm Hg) | SPAP (mm Hg) | TV VTI/LVOT VTI | Ejection Fraction (%) |
|----------|-----------------|-------------|---------------|---------------|-------------|-----------------------------|---------------------------|----------------------|--------------|----------------|----------------------|
| 1        | 38              | 8           | 19            | 6             | NM          | None                         | None                      | 31                   | 17           | 3.5            | 50-55                |
| 2        | 46              | 6           | 31            | 8             | 260         | Severe                        | Severe                    | 36                   | 21           | 7.7            | AF                   |
| 3        | 50              | 7           | 32            | 8             | 196         | Severe                        | Severe                    | 37                   | 23           | 5.6            | AF                   |
| 4        | 37              | 5           | 32            | 6             | 196         | Mild                          | Moderate                  | 50                   | 23           | 5.6            | AF                   |
| 5        | 36              | 7           | 32            | 5             | 218         | Moderate to severe            | Moderate                  | 50                   | 23           | 5.6            | AF                   |
| 6        | 36              | 7           | 32            | 5             | 218         | Mild                          | Moderate                  | 50                   | 23           | 5.6            | AF                   |
| 7        | 36              | 7           | 32            | 5             | 218         | Moderate to severe            | Moderate                  | 50                   | 23           | 5.6            | AF                   |
| 8        | 36              | 7           | 32            | 5             | 218         | Moderate to severe            | Moderate                  | 50                   | 23           | 5.6            | AF                   |
| 9        | 36              | 7           | 32            | 5             | 218         | Moderate to severe            | Moderate                  | 50                   | 23           | 5.6            | AF                   |
| 10       | 36              | 7           | 32            | 5             | 218         | Moderate to severe            | Moderate                  | 50                   | 23           | 5.6            | AF                   |
| 11       | 36              | 7           | 32            | 5             | 218         | Moderate to severe            | Moderate                  | 50                   | 23           | 5.6            | AF                   |
| 12       | 36              | 7           | 32            | 5             | 218         | Moderate to severe            | Moderate                  | 50                   | 23           | 5.6            | AF                   |

Table 2, Table 4, Figure 1, and Figure 2. In 1 patient, whose systolic pulmonary artery pressure was high after TTViV (40 mmHg), no significant change was observed in the NYHA functional class at follow-up (patient number 2). In the other 11 patients, the NYHA functional class improved to less

TTViV, Transcatheter tricuspid valve-in-valve; RV, Right ventricle; RVs'm, Right ventricular peak systolic myocardial velocity; RA, Right atrium; TV MPG, Transvalvular mean pressure gradient; TV PHT, Tricuspid Valve Pressure Half time; VTI, Velocity time index; LVOT, Left ventricle outflow tract; TR, Tricuspid Regurgitation; SPAP, Systolic pulmonary arterial pressure; AF, Atrial fibrillation, NM, Not measurable
### Table 3. Valve characteristics at baseline, degeneration mode, and procedural access

| Case No. | Failed Valve | Failed Valve Size (mm) | Failure Mode | Access | Implanted Valve Brand | Implanted Valve Size (mm) | Follow-up (y) |
|----------|--------------|------------------------|--------------|--------|------------------------|----------------------------|---------------|
| 1        | Pericarp     | 29                     | R            | RFV    | SAPIEN 3               | 29                         | 2             |
| 2        | Mosaic       | 31                     | R+S          | RFV    | SAPIEN XT              | 29                         | 4             |
| 3        | Perimount    | 29                     | R            | RFV    | SAPIEN 3               | 29                         | 3             |
| 4        | Epic         | 29                     | R+S          | RFV    | SAPIEN 3               | 29                         | 1             |
| 5        | Hancock      | 31                     | R            | RFV    | SAPIEN 3               | 29                         | 1             |
| 6        | Hancock™     | 29                     | R            | RFV    | SAPIEN 3               | 26                         | 3             |
| 7        | Biocor       | 27                     | S            | RFV    | SAPIEN 3               | 26                         | 2             |
| 8        | Mosaic       | 29                     | R            | RFV    | SAPIEN XT              | 26                         | 3             |
| 9        | Epic         | 31                     | R+S          | RFV    | SAPIEN 3               | 29                         | 5             |
| 10       | Mosaic       | 31                     | R+S          | RFV    | SAPIEN XT              | 29                         | 6             |
| 11       | Hancock      | 29                     | R+S          | RFV    | SAPIEN XT              | 26                         | 6             |
| 12       | Hancock      | 31                     | R            | RFV    | SAPIEN 3               | 26                         | 2             |

TTViV, Transcatheter tricuspid valve-in-valve; R, Regurgitation; S, Stenosis; RFV, Right femoral vein

### Table 4. Echocardiographic characteristics after TTViV at the midterm follow-up

| Case No. | RV diameter (mm) | RVSM (cm/s) | RA volume (cc/m²) | TV MPG* (mm Hg) | TV PHT (ms) | iEOA (cm²/m²) | Transvalvular regurgitation | Paravalvular regurgitation | TR Gradient (mmHg) | SPAP (mmHg) | TV .VIT/LVOT.VIT | NYHA functional class | LVEF (%) | Rhythm |
|----------|------------------|------------|------------------|-----------------|-------------|---------------|-----------------------------|--------------------------|---------------------|--------------|------------------|----------------------|----------|--------|
| 1        | 33               | 7          | 31               | 5               | 1           | 0.7           | Mild to moderate            | None                     | 30                  | 35           | 16               | 19                   | 50-55    | AF     |
| 2        | 37               | 5          | 85               | 4.5             | 234         | 6.75          | Mild to moderate            | None                     | 40                  | 40           | 21               | 19                   | 55-60    | Sinus  |
| 3        | 36               | 7          | 52               | 5.292           | 128         | 6.75          | Mild to moderate            | None                     | 36                  | 40           | 21               | 19                   | 55-60    | Sinus  |
| 4        | 28               | 6          | 57               | 5               | 110         | 0.7           | Trace                       | None                     | 57                  | 4           | 16               | 19                   | 50-55    | Sinus  |
| 5        | 33               | 6          | 36               | 5               | 205         | 0.7           | Trace                       | None                     | 36                  | 4           | 16               | 19                   | 50-55    | Sinus  |
| 6        | 23               | 2           | 41               | 6               | 221         | 6.99          | None                        | None                     | 41                  | 6           | 16               | 19                   | 50-55    | Sinus  |
| 7        | 29               | 2           | 20               | 6               | 80          | 0.99          | None                        | None                     | 20                  | 6           | 16               | 19                   | 50-55    | Sinus  |
| 8        | 35               | 2           | 20               | 4               | 216         | 0.69          | None                        | None                     | 20                  | 4           | 16               | 19                   | 50-55    | Sinus  |
| 9        | 32               | 2           | 110              | 8               | 153         | 0.59          | None                        | None                     | 110                 | 8           | 16               | 19                   | 50-55    | Sinus  |
| 10       | 34               | 2           | 110              | 8               | 196         | 0.59          | None                        | None                     | 110                 | 8           | 16               | 19                   | 50-55    | Sinus  |
| 11       | 35               | 2           | 20               | 4               | 153         | 0.59          | None                        | None                     | 20                  | 4           | 16               | 19                   | 50-55    | Sinus  |
| 12       | 37               | 2           | 20               | 4               | 196         | 0.59          | None                        | None                     | 20                  | 4           | 16               | 19                   | 50-55    | Sinus  |

TTViV, Transcatheter tricuspid valve-in-valve; TV MPG, Transvalvular mean pressure gradient; TV HVT, Tricuspid valve pressure half time; iEOA, Indexed effective orifice area; RV, Right ventricle; RA, Right atrium; VTI, Velocity time index; LVOT, Left ventricular outflow tract; TR, Tricuspid Regurgitation; SPAP, Systolic pulmonary arterial pressure; NYHA, New York Heart Association; AF, Atrial fibrillation; LVEF, Left ventricular ejection fraction; NM, Not measurable

* MPG was not measured in anemia and/or tachycardia. In atrial fibrillation rhythm, a mean of 5 beats was measured.

### Table 5. Descriptive characteristics of echocardiographic parameters before the procedure and at follow-up

| Case No. | Before TTViV | Follow-up after TViV |
|----------|--------------|----------------------|
|          | N | Mean±SD | Mini-mum | Maxi-mum | N | Mean±SD | Mini-mum | Maxi-mum | P* |
| RV diameter (mm) | 12 | 35.92±7.22 | 25 | 50 | 12 | 32.25±3.47 | 27 | 37 | 0.054 |
| TV MPG (mm) | 12 | 7.08±1.98 | 5 | 11 | 12 | 5.92±1.63 | 2 | 8 | 0.028 |
| TV PHT (mm) | 10 | 245.00±49.46 | 191 | 350 | 11 | 158.64±57.41 | 80 | 234 | 0.011 |
| RVSM | 12 | 6.92±1.31 | 5 | 9 | 12 | 6.75±1.22 | 5 | 9 | 0.564 |
| TRG | 11 | 39.91±7.31 | 30 | 53 | 8 | 26.75±8.99 | 16 | 45 | 0.012 |
| SPAP | 11 | 27.27±7.04 | 17 | 43 | 8 | 34.25±10.32 | 21 | 55 | 0.050 |
| LVEF (%) | 12 | 47.71±4.70 | 40 | 55 | 12 | 49.79±4.58 | 42 | 57.5 | 0.046 |

TTViV, Transcatheter tricuspid valve-in-valve; RV, Right ventricle; TV MPG, Transvalvular mean pressure gradient; TVPHT, Tricuspid valve pressure half time; TRG, Tricuspid regurgitation gradient; SPAP, Systolic pulmonary arterial pressure; LVEF, Left ventricular ejection fraction

P* was obtained using the Wilcoxon signed ranks test.
Comparisons between echocardiographic measurements before the procedure and at follow-up are presented in Table 5. The following characteristics showed significant improvements: transvalvular MPG decreased from 7.08±1.98 mmHg to 5.29±1.63 mmHg (P=0.028), tricuspid valve pressure half time decreased from 245.00 ±49.46 ms to 158.64±57.41 ms (P=0.011), tricuspid regurgitation gradient decreased from 39.91±7.31 mmHg to 26.75±8.99 mmHg (P=0.012), and left ventricular ejection fraction increased from 47.71±7.70% to 49.79±4.58% (P=0.046).

**Discussion**

This study presents the results of the midterm echocardiographic follow-up of patients who underwent TTViV because of degenerative bioprosthetic valves as the first single-center report from Iran. The efficacy and safety of TTViV in our center were compatible with the results of previous international reports.

Transcatheter valve-in-valve implantation is a universally accepted procedure for patients with degenerated bioprosthetic valves who are considered high risk for surgical operations.8,9 Nevertheless, there are limited data on the clinical and echocardiographic outcomes of patients undergoing the TTViV procedure. It has been shown that postprocedural hemodynamics and clinical outcomes are favorable at the 3-year follow-up of patients undergoing TTViV.10,11 In the study of 4 patients treated with the TTViV procedure (using Edwards SAPIEN-
XT and SAPIEN-3 bioprosthesis valves), significant improvements were reported in the transvalvular MPG, right atrial pressure, and tricuspid valve area. Additionally, after 9 to 47 months of follow-up, only 1 patient was rehospitalized. Overall echocardiographic assessments showed maintained hemodynamic performance. In our study, we documented consistent echocardiographic improvements in transvalvular MPG in a larger number of patients over a longer follow-up time.

In a multicenter study on the 3-year outcome after TTViV in 306 patients, McElhinney et al. reported 3 major complications of this procedure: endocarditis (17%), tricuspid valve dysfunction (8%), and thrombosis (12%). Although the number of patients was small in the current report compared with their study, we had no case of infective endocarditis during our patients’ follow-up.

Thrombosis is a rare and acute complication that occurs in the first 6 months following the TTViV procedure. Therefore, anticoagulation therapy in TTViV is needed because of risk factors, such as atrial fibrillation and right heart dilation and failure. As mentioned before, in our patients, anticoagulation therapy was initiated accordingly, and none of them experienced postprocedural thrombosis.

Godart et al. published a multicentric study of TTViV in 10 patients (using 22 mm Melody valves in 7 patients and Edwards SAPIEN valves in 3 patients) and reported improvements in NYHA functional class in 9 patients, significant improvements in transvalvular MPG, and no more-than-trivial regurgitation. A review of data from 71 patients who underwent TTViV (using Melody valves in 41 patients, Edwards SAPIEN valves in 29 patients, and the Braile valve in 1 patient) also showed similar short-term results. Our study, albeit a single-center one, also showed consistent improvements in NYHA functional class, transvalvular MPG, and similar findings in valve regurgitation at the midterm follow-up.

With proven techniques in the transcatheter aortic valve implantation method, the insertion of Edwards SAPIEN bioprosthesis tricuspid valves using femoral vein access is achievable. The transfemoral approach for TTViV, using new generations of balloon expandable devices, is a safe and effective treatment method for tricuspid bioprosthetic valve regurgitation. In a study on patients treated with TTViV at the San Raffaele Scientific Institute in Milan, there were no complications at 30-day postprocedural evaluation, and the patients experienced improvements in renal function and hepatic congestion and function. A successful case of TTViV with favorable symptomatic and hemodynamic outcomes in a 21-year-old woman with severe tricuspid regurgitation has also been reported. Our study also showed no acute or early complications during and after the procedure and revealed improved clinical symptoms in all living patients after a mean time of over 3 years; however, we focused on echocardiographic characteristics rather than paraclinical data.

The first data of transcatheter valve-in-valve procedure in Iran was reported by Haji Zeinali et al. who showed acceptable mid-term results after the valve-in-valve treatment of different failing bioprosthetic valves (2 mitral, 1 pulmonary, and 2 tricuspid valves) in a case series of 5 patients. The patients had manageable postprocedural complications, including pleural effusions and transient ischemic attacks; furthermore, at follow-up, the patients had improved NYHA functional class without paravalvular leakage or valve thrombosis. Our study focused on transcatheter valve-in-valve replacement only in the tricuspid position and found no postprocedural adverse events, valve thrombosis, and trans- and/or paravalvular regurgitation at a longer follow-up of 12 patients.

Due to the relatively small number of patients and incomplete follow-up in some cases, which led to missing data, we are aware that the computed transvalvular MPG after TTViV (Figure 1 and Figure 2) could be biased. We encourage further prospective studies with larger numbers of patients on this subject.

**Conclusion**

In the current study, we reported a single-center successful TTViV procedure that was found to be a safe and effective alternative treatment method for cardiac surgery in patients suffering from degenerated bioprosthetic valves. The procedure had favorable echocardiographic and clinical outcomes and no major complications.

**Acknowledgments**

This study was approved and supported by Tehran Heart Center, Tehran University of Medical Sciences.

**References**

1. Webb JG, Wood DA, Ye J, Gurvitch R, Masson JB, Rodés-Cabau J, Osten M, Horlick E, Wendler O, Dumont E, Carere RG, Wijesinghe N, Nieltschbach F, Johnson M, Thompson CR, Moss R, Leipsic J, Munt B, Lichtenstein SV, Cheung A. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation 2010;121:1848-1857.
2. Jeganathan R, Armstrong S, Al-Alao B, David T. The risk and outcomes of reoperative tricuspid valve surgery. Ann Thorac Surg 2013;95:119-124.
3. Panaich SS, Eleid MF. Tricuspid valve-in-valve implantation for failing bioprosthetic valves: an evolving standard of care. Ann Transl Med 2016;4:410.
4. Praz F, George I, Kodali S, Koulogiannis KP, Gillam LD, Bechis MZ, Rubenson D, Li W, Duncan A. Transcatheter Tricuspid Valve-in-Valve Intervention for Degenerative Bioprosthetic Tricuspid Valve Disease. J Am Soc Echocardiogr 2018;31:491-504.
5. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener
10. Scarsini R, Lunardi M, Pesarini G, Castrioni F, Foola M, Ferrero V, Faggian G, Vassanelli C, Ribichini F. Long-term follow-up after trans-catheter tricuspid valve-in-valve replacement with balloon-expandable aortic valves. Int J Cardiol 2017;235:141-146.
11. Muraru D, Mihaila-Baldea S, Badano LP. Transcatheter Tricuspid Valve Replacement: Taking it One Step Further. J Am Coll Cardiol 2019;73:158-160.
12. Godart F, Barreteau AE, Petit J, Riou JY, Sassolas F, Lusson JR, Fraisse A, Boudjemline Y. Transcatheter tricuspid valve implantation: a multicentre French study. Arch Cardiovasc Dis 2014;107:583-591.
13. Ruparelia N, Mangieri A, Ancona M, Giannini F, Agricola E, Montorfano M, De Bonis M, Alfieri O, Colombo A, Labib A. Percutaneous Transcatheter Treatment for Tricuspid Bioprosthetic Valve Failure. Catheter Cardiovasc Interv 2016;88:994-1001.
14. Condado J, Leonard R, Babalaria V. Percutaneous tricuspid valve-In-ring replacement for the treatment of recurrent severe tricuspid regurgitation. Catheter Cardiovasc Interv 2015;86:1294-1298.
15. Haji Zeinali AM, Abbasi K, Saheb Jam M, Yazdani S, Mortazavi SH. Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with midterm follow-up). J Cardiovasc Thorac Res 2017;9:152-157.